Quantcast

Oral dissolving film formulation developer CURE Pharmaceutical sets terms for $12 million IPO


Shutterstock photo

CURE Pharmaceutical Holding, which is developing oral dissolving film formulations of existing pharmaceutical drugs, announced terms for its IPO on Friday. Its stock is currently traded on the OTCQX under the symbol CURR. 

The Oxnard, CA-based company plans to raise $12 million by offering 2 million shares at a price range of $5 to $7. At the midpoint of the proposed range, CURE Pharmaceutical Holding would command a fully diluted market value of $78 million.

CURE Pharmaceutical Holding was founded in 2011 and plans to list on the Nasdaq under the symbol CURR. Network 1 Financial Securities is the sole bookrunner on the deal.

The article Oral dissolving film formulation developer CURE Pharmaceutical sets terms for $12 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs



More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs










Research Brokers before you trade

Want to trade FX?